Nuvation Bio Secures FDA Fast Track For Safusidenib In IDH1- Mutant Glioma

Nuvation Bio (NUVB) said the U.S. FDA granted Fast Track Designation to Safusidenib, its investigational oral therapy for IDH1-mutant glioma. This regulatory milestone supports potential earlier review and trial acceleration, which is generally viewed positively for development-stage biotech prospects.

Analysis

Nuvation Bio (NUVB) said the U.S. FDA granted Fast Track Designation to Safusidenib, its investigational oral therapy for IDH1-mutant glioma. This regulatory milestone supports potential earlier review and trial acceleration, which is generally viewed positively for development-stage biotech prospects.